{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER&page=2", "query": { "condition": "ER", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T09:23:04.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07085767", "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer", "ER Positive Breast Cancer", "HER2 Negative Breast Carcinoma" ], "interventions": [ { "name": "Palazestrant", "type": "DRUG" }, { "name": "Letrozole-matching placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palazestrant matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-11-03", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 28, "location_summary": "Hot Springs, Arkansas • Beverly Hills, California • Santa Barbara, California + 25 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085767" }, { "nct_id": "NCT02752893", "title": "Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-01-30", "completion_date": "2019-04-03", "has_results": false, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752893" }, { "nct_id": "NCT03691493", "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-02-08", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691493" }, { "nct_id": "NCT04054206", "title": "Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "MN-166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediciNova", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 12, "start_date": "2019-06-24", "completion_date": "2020-05-31", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 1, "location_summary": "Garden Grove, California", "locations": [ { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04054206" }, { "nct_id": "NCT00524043", "title": "An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Paliperidone ER", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2007-09", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 12, "location_summary": "Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Leesburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524043" }, { "nct_id": "NCT01547741", "title": "Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1871, "start_date": "2012-04", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 914, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01547741" }, { "nct_id": "NCT02049957", "title": "Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 118, "start_date": "2014-02-13", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 30, "location_summary": "Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049957" }, { "nct_id": "NCT04961996", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Physician's Choice of Endocrine Therapy", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4170, "start_date": "2021-08-27", "completion_date": "2033-09-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 72, "location_summary": "Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04961996" }, { "nct_id": "NCT00071266", "title": "The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intermittent Claudication", "Peripheral Vascular Disease" ], "interventions": [ { "name": "Niacin Extended Release and Lovastatin Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kos Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 870, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-11-02", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071266" }, { "nct_id": "NCT00371345", "title": "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastasis" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dasatinib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2006-12", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-06-11T09:23:04.496Z", "location_count": 7, "location_summary": "San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371345" } ] }